AbbVie (ABBV)

Company Profile

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Company profile

Ticker

ABBV

Exchange

NYSE

Website

www.abbvie.com/

CEO

Richard Gonzalez

Incorporated

Delaware

Location

Illinois

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology (except Nanobiotechnology)

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Bausch Health Companies • Celgene • Perrigo ...

SEC CIK

0001551152

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

AbbVie Aviation LLC • AbbVie Biopharmaceuticals LLC • AbbVie Bioresearch Center Inc. • AbbVie Biotech Ventures Inc. • AbbVie Biotherapeutics Inc. • AbbVie Domestic Holdings Inc. • AbbVie Endocrine Inc. • AbbVie Endocrinology Inc. • AbbVie Finance Corporation • AbbVie Finance LLC ...

IRS number

320375147

ABBV stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$213.50

Low target

$209.00

High target

$218.00

Morgan Stanley

Maintains

Overweight

$218.00

12 Aug 24

Latest filings (excl ownership)

View all

S-8

Registration of securities for employees

7 Aug 24

AbbVie Reports Second-Quarter 2024 Financial Results

25 Jul 24

8-K

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

Conflict minerals disclosure

Departure of Directors or Certain Officers

3 May 24

AbbVie Reports First-Quarter 2024 Financial Results

26 Apr 24

Transcripts

View all

ABBV

Earnings call transcript

2024 Q2

25 Jul 24

ABBV

Earnings call transcript

2024 Q1

26 Apr 24

ABBV

Earnings call transcript

2023 Q4

2 Feb 24

ABBV

Earnings call transcript

2023 Q3

27 Oct 23

ABBV

Earnings call transcript

2023 Q2

27 Jul 23

ABBV

Earnings call transcript

2023 Q2

27 Jul 23

ABBV

Earnings call transcript

2023 Q1

27 Apr 23

ABBV

Earnings call transcript

2022 Q4

9 Feb 23

ABBV

Earnings call transcript

2022 Q3

28 Oct 22

ABBV

Earnings call transcript

2022 Q2

29 Jul 22

Latest ownership filings

View all

144

Notice of proposed sale of securities

Notice of proposed sale of securities

7 Aug 24

144

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart ABBV financial data

Quarter (USD)	Jun 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	13.13 bn	13.13 bn	13.13 bn	13.13 bn	13.13 bn	13.13 bn
Cash burn (monthly)	1.65 bn	(no burn)	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	3.76 bn	n/a	n/a	n/a	n/a	n/a
Cash remaining	9.37 bn	n/a	n/a	n/a	n/a	n/a
Runway (months of cash)	5.7	n/a	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from AbbVie earnings reports.

Institutional ownership, Q2 2024

ABBV institutional ownership history Ownership history

71.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	3208	3180	+0.9%
Opened positions	209	563	-62.9%
Closed positions	181	182	-0.5%
Increased positions	1368	1120	+22.1%
Reduced positions	1236	1220	+1.3%

13F shares	Current	Prev Q	Change
Total value	207.28 tn	205.79 tn	+0.7%
Total shares	1.26 bn	1.19 bn	+5.4%
Total puts	9.65 mm	11.41 mm	-15.4%
Total calls	12.98 mm	15.35 mm	-15.4%
Total put/call ratio	0.7	0.7	+0.0%

Largest owners	Shares	Value	Change
Vanguard	170.66 mm	$29.27 tn	+0.2%
BLK BlackRock	136.43 mm	$23.40 tn	-4.6%
STT State Street	77.80 mm	$13.34 tn	-0.2%
JPM JPMorgan Chase & Co.	53.56 mm	$9.19 tn	+4.5%
Capital International Investors	38.60 mm	$6.62 tn	-19.7%
MS Morgan Stanley	37.24 mm	$6.39 tn	+5.9%
Geode Capital Management	36.68 mm	$6.28 tn	-2.2%
Capital Research Global Investors	33.19 mm	$5.69 tn	+6.0%
Charles Schwab Investment Management	24.97 mm	$4.28 tn	NEW
Norges Bank	22.48 mm	$3.86 tn	NEW

Largest transactions	Shares	Bought/sold	Change
Charles Schwab Investment Management	24.97 mm	+24.97 mm	NEW
Norges Bank	22.48 mm	+22.48 mm	NEW
Capital International Investors	38.60 mm	-9.50 mm	-19.7%
BLK BlackRock	136.43 mm	-6.53 mm	-4.6%
Capital World Investors	10.28 mm	+5.91 mm	+135.2%
BEN Franklin Resources	15.95 mm	+4.81 mm	+43.1%
Boston Partners	4.19 mm	+3.01 mm	+256.7%
TFC Truist Financial	2.88 mm	+2.88 mm	NEW
Credit Suisse	0.00	-2.74 mm	EXIT
GS The Goldman Sachs Group, Inc.	11.61 mm	+2.73 mm	+30.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ABBV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Aug 24	Richard A Gonzalez	Common Stock, $0.01 par value	Sell	Dispose S	No	No	186.52	66,500	12.40 mm	446,599
17 Jul 24	Richard A Gonzalez	Common Stock, $0.01 par value	Sell	Dispose S	No	No	175	282,845	49.50 mm	513,099
17 Jul 24	Richard A Gonzalez	Common Stock, $0.01 par value	Option exercise	Acquire M	No	No	93.5	76,377	7.14 mm	795,944
17 Jul 24	Richard A Gonzalez	Common Stock, $0.01 par value	Option exercise	Acquire M	No	No	79.02	119,418	9.44 mm	719,567
17 Jul 24	Richard A Gonzalez	Common Stock, $0.01 par value	Option exercise	Acquire M	No	No	61.36	87,050	5.34 mm	600,149
17 Jul 24	Richard A Gonzalez	Option Common Stock	Option exercise	Dispose M	No	No	93.5	76,377	7.14 mm	152,755
17 Jul 24	Richard A Gonzalez	Option Common Stock	Option exercise	Dispose M	No	No	79.02	119,418	9.44 mm	59,709
17 Jul 24	Richard A Gonzalez	Option Common Stock	Option exercise	Dispose M	No	No	61.36	87,050	5.34 mm	0
30 Jun 24	Alpern Robert J	Stock Equivalent Units Common Stock	Grant	Acquire A	No	No	171.52	43	7.38 k	9,541
30 Jun 24	Susan E Quaggin	Stock Equivalent Units Common Stock	Grant	Acquire A	No	No	171.52	87	14.92 k	236